
Nuria Porta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8357937/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. New England Journal of Medicine, 2015, 373, 1697-1708.	27.0	1,796
2	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 162-174.	10.7	450
3	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. Cancer Discovery, 2017, 7, 1006-1017.	9.4	341
4	Genomics of lethal prostate cancer at diagnosis and castration resistance. Journal of Clinical Investigation, 2020, 130, 1743-1751.	8.2	180
5	Discordance between reported intention-to-treat and per protocol analyses. Journal of Clinical Epidemiology, 2007, 60, 663-669.	5.0	149
6	Prevalence, risk factors and main features of adverse drug reactions leading to hospital admission. European Journal of Clinical Pharmacology, 2014, 70, 361-367.	1.9	86
7	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology, 2017, 283, 168-177.	7.3	81
8	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer Discovery, 2021, 11, 2812-2827.	9.4	78
9	Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncology, The, 2021, 22, 246-255.	10.7	73
10	Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. Radiotherapy and Oncology, 2018, 126, 155-162.	0.6	72
11	Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. European Urology, 2020, 77, 260-268.	1.9	58
12	Characterizing CDK12-Mutated Prostate Cancers. Clinical Cancer Research, 2021, 27, 566-574.	7.0	50
13	The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis. European Urology, 2020, 77, 344-351.	1.9	41
14	TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations Journal of Clinical Oncology, 2019, 37, 5005-5005.	1.6	35
15	Where do new medicines originate from in the EU?. Nature Reviews Drug Discovery, 2014, 13, 92-93.	46.4	34
16	ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI). International Journal of Gynecological Cancer, 2021, 31, 1471-1475.	2.5	30
17	Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. European Urology, 2022, 82, 273-279.	1.9	29
18	A specific nursing educational program in patients with Cushing's syndrome. Endocrine, 2016, 53, 199-209.	2.3	28

NURIA PORTA

#	Article	IF	CITATIONS
19	Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. Clinical Genitourinary Cancer, 2020, 18, e418-e442.	1.9	28
20	BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology, 2019, 75, 593-601.	1.9	27
21	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycinâ€C vs surgical management in lowâ€risk nonâ€muscleâ€invasive bladder cancer. BJU International, 2020, 125, 817-826.	2.5	27
22	Outcome of BC2001 patients (CRUK/01/004) who received neoadjuvant chemotherapy prior to randomization to chemo-radiotherapy (cRT) versus radiotherapy (RT) Journal of Clinical Oncology, 2017, 35, 298-298.	1.6	27
23	The use of 2D fingerprint methods to support the assessment of structural similarity in orphan drug legislation. Journal of Cheminformatics, 2014, 6, 5.	6.1	23
24	Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiology Imaging Cancer, 2021, 3, e210048.	1.6	22
25	Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. European Urology, 2021, 79, 307-315.	1.9	20
26	PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018). Clinical and Translational Radiation Oncology, 2020, 25, 22-28.	1.7	19
27	BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer Journal of Clinical Oncology, 2017, 35, 280-280.	1.6	15
28	GeneXpert® for smear-negative pulmonary tuberculosis: does it play a role in low-burden countries?. Diagnostic Microbiology and Infectious Disease, 2013, 75, 325-326.	1.8	14
29	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European Urology Focus, 2018, 4, 235-244.	3.1	14
30	Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer. Journal of Clinical Oncology, 2019, 37, 2182-2184.	1.6	13
31	Image Contrast, Image Pre-Processing, and T1 Mapping Affect MRI Radiomic Feature Repeatability in Patients with Colorectal Cancer Liver Metastases. Cancers, 2021, 13, 240.	3.7	12
32	The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma. British Journal of Cancer, 2015, 113, 1275-1281.	6.4	11
33	Biomarkers for site-specific response to neoadjuvant chemotherapy in epithelial ovarian cancer: relating MRI changes to tumour cell load and necrosis. British Journal of Cancer, 2021, 124, 1130-1137.	6.4	11
34	The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). British Journal of Cancer, 2017, 116, 649-657.	6.4	9
35	Molecular similarity considerations in the licensing of orphan drugs. Drug Discovery Today, 2017, 22, 377-381.	6.4	9
36	Hypo-Fractionation in Muscle-Invasive Bladder Cancer: An Individual Patient Data (IPD) Meta-Analysis of the BC2001 and BCON Trials. International Journal of Radiation Oncology Biology Physics, 2019, 105, S138.	0.8	9

NURIA PORTA

#	Article	IF	CITATIONS
37	A dynamic model for the risk of bladder cancer progression. Statistics in Medicine, 2012, 31, 287-300.	1.6	7
38	Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clinical Cancer Research, 2022, 28, 1323-1334.	7.0	7
39	Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2018, 36, 5013-5013.	1.6	5
40	Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC) Journal of Clinical Oncology, 2016, 34, 5014-5014.	1.6	3
41	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC Journal of Clinical Oncology, 2017, 35, 135-135.	1.6	3
42	Prospective comparison of whole body MRI and FDG PET/CT for detection of multiple myeloma and correlation with markers of disease burden: Results of the iTIMM trial Journal of Clinical Oncology, 2021, 39, 8012-8012.	1.6	2
43	Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial Journal of Clinical Oncology, 2017, 35, 141-141.	1.6	2
44	Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer. , 2015, , .		2
45	2507 Prognostic factors in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). European Journal of Cancer, 2015, 51, S475-S476.	2.8	1
46	Quality of life (QL) of patients (pts) treated for muscle invasive bladder cancer (MIBC) with radiotherapy (RT) +/- chemotherapy (CT) in the BC2001 trial (CRUK/01/004): Analysis of impact of treatment at an individual level Journal of Clinical Oncology, 2017, 35, 292-292.	1.6	1
47	Transplantation: clinical studies - A. Nephrology Dialysis Transplantation, 2013, 28, i275-i292.	0.7	0
48	2642 The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 (CRUK/01/004) trial. European Journal of Cancer, 2015, 51, S527-S528.	2.8	0
49	Dynamic prediction methods in the BC2001 clinical trial. Trials, 2015, 16, .	1.6	0
50	2579 Evaluation of clinical decision-making and the use of circulating tumor cells (CTCs) by physicians treating castration-resistant prostate cancer (CRPC). European Journal of Cancer, 2015, 51, S504.	2.8	0
51	Patient reported outcomes following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials. Presented on behalf of the START Trial Management Group. European Journal of Cancer, 2017, 72, S5-S6.	2.8	0
52	Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260–8. European Urology, 2020, 77, e156-e157.	1.9	0
53	Reply to Santhanam Sundar and Paul Symonds' Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. Eur Urol 2021;79:307–15. European Urology. 2021. 80. e51-e52.	1.9	0

54 Hypofractionation: less is more?. Oncotarget, 2021, 12, 1729-1733.

1.8 0

NURIA PORTA

#	Article	IF	CITATIONS
55	815TiP ENGOT/GYN1/NCRI: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ATARI). Annals of Oncology, 2021, 32, S768.	1.2	Ο
56	Clinical and radiological characteristics of metastatic prostate cancer (mPCa) patients (pts) with liver metastases (LM) and association with overall survival (OS) Journal of Clinical Oncology, 2016, 34, 5043-5043.	1.6	0
57	Abstract 4340: DNA repair genes aberrations in germline DNA in metastatic castration-resistant prostate cancer patients. , 2016, , .		0
58	Abstract 3973: Diffusion-weighted imaging of bone metastases as treatment response biomarker in prostate cancer. , 2016, , .		0